|
| Featured Event |
Aug 13, 2008
4:30 PM ET
|
Canaccord Adams 28th Annual Global Growth Conference
Speaker: Michael D. Kishbauch, President & Chief Executive Officer
The presentation to which you are about to listen contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding future clinical trial activity for elvucitabine; future preclinical activity and candidate nomination of HCV compounds under Achillion's collaboration with Gilead Sciences, Inc.; further preclinical development and regulatory filings for ACH-702; estimates of 2007 financial performance and year-end cash balance; and the expectation that Achillion will have sufficient cash to support its current operating plan through at least December 31, 2008. Such statements are subject to numerous factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that any product candidate Achillion is developing will successfully complete necessary preclinical and clinical development phases, be approved for sale in any market or that, if approved, revenue from sales of such product will reach any specific level. In particular, management's expectations could be affected by risks and uncertainties relating to: results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities and investigational review boards at clinical trial sites; Achillion's ability to enroll patients in its clinical trials; Achillion's ability to obtain additional funding required to conduct its research, development and commercialization activities; unplanned cash requirements and expenditures; and Achillion's ability to obtain, maintain and enforce patent and other intellectual property protection for any products it is developing. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" included Achillion's quarterly report on Form 10-Q for the quarter ended September 30, 2006, as filed with the Securities and Exchange Commission on November 17, 2006. Further, any forward-looking statements contained in this presentation speak only as the date of the original presentation, and Achillion expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
|
| Upcoming Events |
| Details on upcoming events are not yet available. Please click here to be notified of all upcoming events. |
| Archived Events |
Aug 12, 2008
4:30 PM ET
|
Achillion Pharmaceuticals' Second Quarter 2008 Earnings and Program Update Call
|
Jun 11, 2008
11:30 AM ET
|
Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference.
Speaker: Michael D. Kishbauch, President & Chief Executive Officer
The presentation to which you are about to listen contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding future clinical trial activity for elvucitabine; future preclinical activity and candidate nomination of HCV compounds under Achillion's collaboration with Gilead Sciences, Inc.; further preclinical development and regulatory filings for ACH-702; estimates of 2007 financial performance and year-end cash balance; and the expectation that Achillion will have sufficient cash to support its current operating plan through at least December 31, 2008. Such statements are subject to numerous factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that any product candidate Achillion is developing will successfully complete necessary preclinical and clinical development phases, be approved for sale in any market or that, if approved, revenue from sales of such product will reach any specific level. In particular, management's expectations could be affected by risks and uncertainties relating to: results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities and investigational review boards at clinical trial sites; Achillion's ability to enroll patients in its clinical trials; Achillion's ability to obtain additional funding required to conduct its research, development and commercialization activities; unplanned cash requirements and expenditures; and Achillion's ability to obtain, maintain and enforce patent and other intellectual property protection for any products it is developing. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" included Achillion's quarterly report on Form 10-Q for the quarter ended September 30, 2006, as filed with the Securities and Exchange Commission on November 17, 2006. Further, any forward-looking statements contained in this presentation speak only as the date of the original presentation, and Achillion expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
|
Apr 9, 2008
2:30 PM ET
|
Hepatitis- C Investor Conference
Speaker: Elizabeth Olek,D.O., Vice President and Chief Medical Officer
The presentation to which you are about to listen contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding future clinical trial activity for elvucitabine; future preclinical activity and candidate nomination of HCV compounds under Achillion's collaboration with Gilead Sciences, Inc.; further preclinical development and regulatory filings for ACH-702; estimates of 2007 financial performance and year-end cash balance; and the expectation that Achillion will have sufficient cash to support its current operating plan through at least December 31, 2008. Such statements are subject to numerous factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that any product candidate Achillion is developing will successfully complete necessary preclinical and clinical development phases, be approved for sale in any market or that, if approved, revenue from sales of such product will reach any specific level. In particular, management's expectations could be affected by risks and uncertainties relating to: results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities and investigational review boards at clinical trial sites; Achillion's ability to enroll patients in its clinical trials; Achillion's ability to obtain additional funding required to conduct its research, development and commercialization activities; unplanned cash requirements and expenditures; and Achillion's ability to obtain, maintain and enforce patent and other intellectual property protection for any products it is developing. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" included Achillion's quarterly report on Form 10-Q for the quarter ended September 30, 2006, as filed with the Securities and Exchange Commission on November 17, 2006. Further, any forward-looking statements contained in this presentation speak only as the date of the original presentation, and Achillion expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
|
Mar 17, 2008
3:15 PM ET
|
Cowen and Company 28th Annual Health Care Conference
Speaker: Michael D. Kishbauch, President and Chief Executive Officer
The Boston Marriott Copley Place
The presentation to which you are about to listen contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding future clinical trial activity for elvucitabine; future preclinical activity and candidate nomination of HCV compounds under Achillion's collaboration with Gilead Sciences, Inc.; further preclinical development and regulatory filings for ACH-702; estimates of 2007 financial performance and year-end cash balance; and the expectation that Achillion will have sufficient cash to support its current operating plan through at least December 31, 2008. Such statements are subject to numerous factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that any product candidate Achillion is developing will successfully complete necessary preclinical and clinical development phases, be approved for sale in any market or that, if approved, revenue from sales of such product will reach any specific level. In particular, management's expectations could be affected by risks and uncertainties relating to: results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities and investigational review boards at clinical trial sites; Achillion's ability to enroll patients in its clinical trials; Achillion's ability to obtain additional funding required to conduct its research, development and commercialization activities; unplanned cash requirements and expenditures; and Achillion's ability to obtain, maintain and enforce patent and other intellectual property protection for any products it is developing. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" included Achillion's quarterly report on Form 10-Q for the quarter ended September 30, 2006, as filed with the Securities and Exchange Commission on November 17, 2006. Further, any forward-looking statements contained in this presentation speak only as the date of the original presentation, and Achillion expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
|
Mar 5, 2008
3:15 PM
|
SFG's Second Annual SIGnificant Options in Healthcare Conference
Speaker: Dr. Michael Pucci, Senior Director, Antimicrobial Drug Discovery
|
Feb 27, 2008
4:30 PM ET
|
Achillion Pharmaceuticals' Fourth Quarter and Year End 2007 Earnings and Program Update Call
|
Feb 12, 2008
2:00 PM ET
|
BIO CEO & Investor Conference
Speaker: Michael D. Kishbauch, President & Chief Executive Officer
New York City
he presentation to which you are about to listen contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding future clinical trial activity for elvucitabine; future preclinical activity and candidate nomination of HCV compounds under Achillion's collaboration with Gilead Sciences, Inc.; further preclinical development and regulatory filings for ACH-702; estimates of 2007 financial performance and year-end cash balance; and the expectation that Achillion will have sufficient cash to support its current operating plan through at least December 31, 2008. Such statements are subject to numerous factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that any product candidate Achillion is developing will successfully complete necessary preclinical and clinical development phases, be approved for sale in any market or that, if approved, revenue from sales of such product will reach any specific level. In particular, management's expectations could be affected by risks and uncertainties relating to: results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities and investigational review boards at clinical trial sites; Achillion's ability to enroll patients in its clinical trials; Achillion's ability to obtain additional funding required to conduct its research, development and commercialization activities; unplanned cash requirements and expenditures; and Achillion's ability to obtain, maintain and enforce patent and other intellectual property protection for any products it is developing. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" included Achillion's quarterly report on Form 10-Q for the quarter ended September 30, 2006, as filed with the Securities and Exchange Commission on November 17, 2006. Further, any forward-looking statements contained in this presentation speak only as the date of the original presentation, and Achillion expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
|
Nov 27, 2007
2:30 PM ET
|
Lazard Capital Markets Fourth Annual Healthcare Conference
Speaker: Michael D. Kishbauch, President and Chief Executive Officer
The New York Palace Hotel
The presentation to which you are about to listen contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding future clinical trial activity for elvucitabine; future preclinical activity and candidate nomination of HCV compounds under Achillion's collaboration with Gilead Sciences, Inc.; further preclinical development and regulatory filings for ACH-702; estimates of 2007 financial performance and year-end cash balance; and the expectation that Achillion will have sufficient cash to support its current operating plan through at least December 31, 2008. Such statements are subject to numerous factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that any product candidate Achillion is developing will successfully complete necessary preclinical and clinical development phases, be approved for sale in any market or that, if approved, revenue from sales of such product will reach any specific level. In particular, management's expectations could be affected by risks and uncertainties relating to: results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities and investigational review boards at clinical trial sites; Achillion's ability to enroll patients in its clinical trials; Achillion's ability to obtain additional funding required to conduct its research, development and commercialization activities; unplanned cash requirements and expenditures; and Achillion's ability to obtain, maintain and enforce patent and other intellectual property protection for any products it is developing. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" included Achillion's quarterly report on Form 10-Q for the quarter ended September 30, 2006, as filed with the Securities and Exchange Commission on November 17, 2006. Further, any forward-looking statements contained in this presentation speak only as the date of the original presentation, and Achillion expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
|
Nov 13, 2007
11:30 AM
|
JMP Securities Section Focus Conference
Speaker: Michael D. Kishbauch, President and Chief Executive Officer
Four Seasons Hotel
Boston, MA
The presentation to which you are about to listen contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding future clinical trial activity for elvucitabine; future preclinical activity and candidate nomination of HCV compounds under Achillion's collaboration with Gilead Sciences, Inc.; further preclinical development and regulatory filings for ACH-702; estimates of 2007 financial performance and year-end cash balance; and the expectation that Achillion will have sufficient cash to support its current operating plan through at least December 31, 2008. Such statements are subject to numerous factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that any product candidate Achillion is developing will successfully complete necessary preclinical and clinical development phases, be approved for sale in any market or that, if approved, revenue from sales of such product will reach any specific level. In particular, management's expectations could be affected by risks and uncertainties relating to: results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities and investigational review boards at clinical trial sites; Achillion's ability to enroll patients in its clinical trials; Achillion's ability to obtain additional funding required to conduct its research, development and commercialization activities; unplanned cash requirements and expenditures; and Achillion's ability to obtain, maintain and enforce patent and other intellectual property protection for any products it is developing. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" included Achillion's quarterly report on Form 10-Q for the quarter ended September 30, 2006, as filed with the Securities and Exchange Commission on November 17, 2006. Further, any forward-looking statements contained in this presentation speak only as the date of the original presentation, and Achillion expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
|
Nov 6, 2007
10:15 AM ET
|
Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Speaker: Michael D. Kishbauch, President and Chief Executive Officer
New York Palace Hotel
New York, NY
The presentation to which you are about to listen contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding future clinical trial activity for elvucitabine; future preclinical activity and candidate nomination of HCV compounds under Achillion's collaboration with Gilead Sciences, Inc.; further preclinical development and regulatory filings for ACH-702; estimates of 2007 financial performance and year-end cash balance; and the expectation that Achillion will have sufficient cash to support its current operating plan through at least December 31, 2008. Such statements are subject to numerous factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that any product candidate Achillion is developing will successfully complete necessary preclinical and clinical development phases, be approved for sale in any market or that, if approved, revenue from sales of such product will reach any specific level. In particular, management's expectations could be affected by risks and uncertainties relating to: results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities and investigational review boards at clinical trial sites; Achillion's ability to enroll patients in its clinical trials; Achillion's ability to obtain additional funding required to conduct its research, development and commercialization activities; unplanned cash requirements and expenditures; and Achillion's ability to obtain, maintain and enforce patent and other intellectual property protection for any products it is developing. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" included Achillion's quarterly report on Form 10-Q for the quarter ended September 30, 2006, as filed with the Securities and Exchange Commission on November 17, 2006. Further, any forward-looking statements contained in this presentation speak only as the date of the original presentation, and Achillion expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
|
Nov 5, 2007
1:55 PM ET
|
CIBC World Markets 18th Annual Healthcare Conference
Speaker: Michael D. Kishbauch, President and Chief Executive Officer
Waldorf-Astoria Hotel
New York, NY
The presentation to which you are about to listen contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding future clinical trial activity for elvucitabine; future preclinical activity and candidate nomination of HCV compounds under Achillion's collaboration with Gilead Sciences, Inc.; further preclinical development and regulatory filings for ACH-702; estimates of 2007 financial performance and year-end cash balance; and the expectation that Achillion will have sufficient cash to support its current operating plan through at least December 31, 2008. Such statements are subject to numerous factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that any product candidate Achillion is developing will successfully complete necessary preclinical and clinical development phases, be approved for sale in any market or that, if approved, revenue from sales of such product will reach any specific level. In particular, management's expectations could be affected by risks and uncertainties relating to: results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities and investigational review boards at clinical trial sites; Achillion's ability to enroll patients in its clinical trials; Achillion's ability to obtain additional funding required to conduct its research, development and commercialization activities; unplanned cash requirements and expenditures; and Achillion's ability to obtain, maintain and enforce patent and other intellectual property protection for any products it is developing. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" included Achillion's quarterly report on Form 10-Q for the quarter ended September 30, 2006, as filed with the Securities and Exchange Commission on November 17, 2006. Further, any forward-looking statements contained in this presentation speak only as the date of the original presentation, and Achillion expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
|
Sep 20, 2007
8:30 AM
|
Achillion to Present At the First Annual Maxim Group Growth Conference
Grand Hyatt Hotel, New York
|
May 23, 2007
1:30 PM ET
|
Sixth Annual JMP Securities Research Conference
Speaker: Michael D. Kishbauch, President and Chief Executive Officer
The presentation to which you are about to listen contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding future clinical trial activity for elvucitabine; future preclinical activity and candidate nomination of HCV compounds under Achillion's collaboration with Gilead Sciences, Inc.; further preclinical development and regulatory filings for ACH-702; estimates of 2007 financial performance and year-end cash balance; and the expectation that Achillion will have sufficient cash to support its current operating plan through at least December 31, 2008. Such statements are subject to numerous factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that any product candidate Achillion is developing will successfully complete necessary preclinical and clinical development phases, be approved for sale in any market or that, if approved, revenue from sales of such product will reach any specific level. In particular, management's expectations could be affected by risks and uncertainties relating to: results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities and investigational review boards at clinical trial sites; Achillion's ability to enroll patients in its clinical trials; Achillion's ability to obtain additional funding required to conduct its research, development and commercialization activities; unplanned cash requirements and expenditures; and Achillion's ability to obtain, maintain and enforce patent and other intellectual property protection for any products it is developing. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" included Achillion's quarterly report on Form 10-Q for the quarter ended September 30, 2006, as filed with the Securities and Exchange Commission on November 17, 2006. Further, any forward-looking statements contained in this presentation speak only as the date of the original presentation, and Achillion expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
|
Apr 11, 2007
3:00 PM ET
|
CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
Speaker: Michael D. Kishbauch, President and Chief Executive Officer
The presentation to which you are about to listen contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding future clinical trial activity for elvucitabine; future preclinical activity and candidate nomination of HCV compounds under Achillion's collaboration with Gilead Sciences, Inc.; further preclinical development and regulatory filings for ACH-702; estimates of 2007 financial performance and year-end cash balance; and the expectation that Achillion will have sufficient cash to support its current operating plan through at least December 31, 2008. Such statements are subject to numerous factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that any product candidate Achillion is developing will successfully complete necessary preclinical and clinical development phases, be approved for sale in any market or that, if approved, revenue from sales of such product will reach any specific level. In particular, management's expectations could be affected by risks and uncertainties relating to: results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities and investigational review boards at clinical trial sites; Achillion's ability to enroll patients in its clinical trials; Achillion's ability to obtain additional funding required to conduct its research, development and commercialization activities; unplanned cash requirements and expenditures; and Achillion's ability to obtain, maintain and enforce patent and other intellectual property protection for any products it is developing. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" included Achillion's quarterly report on Form 10-Q for the quarter ended September 30, 2006, as filed with the Securities and Exchange Commission on November 17, 2006. Further, any forward-looking statements contained in this presentation speak only as the date of the original presentation, and Achillion expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
|
Mar 29, 2007
2:00 PM
|
Future Leaders in the Biotech Industry
Speaker: Michael D. Kishbauch, President and Chief Executive Officer
The presentation to which you are about to listen contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding future clinical trial activity for elvucitabine; future preclinical activity and candidate nomination of HCV compounds under Achillion's collaboration with Gilead Sciences, Inc.; further preclinical development and regulatory filings for ACH-702; estimates of 2007 financial performance and year-end cash balance; and the expectation that Achillion will have sufficient cash to support its current operating plan through at least December 31, 2008. Such statements are subject to numerous factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that any product candidate Achillion is developing will successfully complete necessary preclinical and clinical development phases, be approved for sale in any market or that, if approved, revenue from sales of such product will reach any specific level. In particular, management's expectations could be affected by risks and uncertainties relating to: results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities and investigational review boards at clinical trial sites; Achillion's ability to enroll patients in its clinical trials; Achillion's ability to obtain additional funding required to conduct its research, development and commercialization activities; unplanned cash requirements and expenditures; and Achillion's ability to obtain, maintain and enforce patent and other intellectual property protection for any products it is developing. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" included Achillion's quarterly report on Form 10-Q for the quarter ended September 30, 2006, as filed with the Securities and Exchange Commission on November 17, 2006. Further, any forward-looking statements contained in this presentation speak only as the date of the original presentation, and Achillion expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
|
Mar 13, 2007
8:00 AM ET
|
Cowen and Company 27th Annual Health Care Conference
Speaker: Michael D. Kishbauch, President and Chief Executive Officer
The presentation to which you are about to listen contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding future clinical trial activity for elvucitabine; future preclinical activity and candidate nomination of HCV compounds under Achillion's collaboration with Gilead Sciences, Inc.; further preclinical development and regulatory filings for ACH-702; estimates of 2007 financial performance and year-end cash balance; and the expectation that Achillion will have sufficient cash to support its current operating plan through at least December 31, 2008. Such statements are subject to numerous factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that any product candidate Achillion is developing will successfully complete necessary preclinical and clinical development phases, be approved for sale in any market or that, if approved, revenue from sales of such product will reach any specific level. In particular, management's expectations could be affected by risks and uncertainties relating to: results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities and investigational review boards at clinical trial sites; Achillion's ability to enroll patients in its clinical trials; Achillion's ability to obtain additional funding required to conduct its research, development and commercialization activities; unplanned cash requirements and expenditures; and Achillion's ability to obtain, maintain and enforce patent and other intellectual property protection for any products it is developing. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" included Achillion's quarterly report on Form 10-Q for the quarter ended September 30, 2006, as filed with the Securities and Exchange Commission on November 17, 2006. Further, any forward-looking statements contained in this presentation speak only as the date of the original presentation, and Achillion expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
|
Mar 1, 2007
|
SIGnificant Investment Options in Healthcare by Susquehanna Financial
Speaker: Michael D. Kishbauch, President and Chief Executive Officer
The presentation to which you are about to listen contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding future clinical trial activity for elvucitabine; future preclinical activity and candidate nomination of HCV compounds under Achillion's collaboration with Gilead Sciences, Inc.; further preclinical development and regulatory filings for ACH-702; estimates of 2007 financial performance and year-end cash balance; and the expectation that Achillion will have sufficient cash to support its current operating plan through at least December 31, 2008. Such statements are subject to numerous factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that any product candidate Achillion is developing will successfully complete necessary preclinical and clinical development phases, be approved for sale in any market or that, if approved, revenue from sales of such product will reach any specific level. In particular, management's expectations could be affected by risks and uncertainties relating to: results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities and investigational review boards at clinical trial sites; Achillion's ability to enroll patients in its clinical trials; Achillion's ability to obtain additional funding required to conduct its research, development and commercialization activities; unplanned cash requirements and expenditures; and Achillion's ability to obtain, maintain and enforce patent and other intellectual property protection for any products it is developing. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" included Achillion's quarterly report on Form 10-Q for the quarter ended September 30, 2006, as filed with the Securities and Exchange Commission on November 17, 2006. Further, any forward-looking statements contained in this presentation speak only as the date of the original presentation, and Achillion expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
|
 = add file to Briefcase
|